KaloBios (KBIO) Surge Continues As Firm Names Martin Shkreli As New CEOMani
KaloBios Pharmaceuticals announced late Thursday that former hedge fund manager Martin Shkreli has become its chief executive officer and chairman after he led a group of investors to buy 70% of the drug developer’s outstanding shares, or as DealBreaker so eloquently put it " Desperate Pharmaceutical Company Hits Rock Bottom, Names Martin Shkreli CEO"- The South San Francisco-based company said Shkreli will work with KalioBios’ senior management team to ensure its continued operations.
Shkreli’s majority . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.